Oncogene Science Inc. said preclinical research indicates that itstransforming growth factor-beta 3 may reduce the incidence,severity and duration of oral mucositis, reduce chemotherapy-associated weight loss and increase survival for cancer patientsundergoing chemotherapy.
Research reported in the March issue of Cancer Researchshowed that the Uniondale, N.Y., company's TGF-Beta 3significantly reduced proliferation of oral epithelium in vitroand in vivo. The findings resulted after TGF-Beta 3 wasadministered topically to the oral mucosa of the Syrian goldenhamster before chemotherapy.
(c) 1997 American Health Consultants. All rights reserved.